Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Top Performance

Predictions

sell
Kezar Life Sciences

Start price
Target price
Perf. (%)
€11.30
16.11.21
-
14.11.22
3.54%
27.11.21

blaugold 
16.11.21 50%
buy
Genocea Biosciences Inc.

Start price
Target price
Perf. (%)
€1.41
16.11.21
-
16.11.22
-32.98%
05.12.21

Mori8 
16.11.21 50%
buy
Eiger Biopharmaceuticals Inc

Start price
Target price
Perf. (%)
€6.66
16.11.21
-
16.11.22
-22.54%
05.12.21

Mori8 
16.11.21 50%
buy
Adaptimmune Therapeutics PLC ADR

Start price
Target price
Perf. (%)
€3.88
16.11.21
-
16.11.22
-2.06%
27.11.21

daimler1 
16.11.21 50%
buy
Novo Nordisk A/S

Start price
Target price
Perf. (%)
€100.08
16.11.21
-
16.11.22
-5.88%
27.11.21

gerihouse 
16.11.21 50%
sell
Bayer AG

Start price
Target price
Perf. (%)
€50.27
15.11.21
-
15.11.22
-9.05%
27.11.21

nero 
15.11.21 0%
buy
Aurinia Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€23.97
15.11.21
-
15.11.22
-28.16%
26.11.21

Could be worthwhile Investment >10% per year
Vassago1 
15.11.21 50%
sell
Amarin Corp. ADR

Start price
Target price
Perf. (%)
€3.40
15.11.21
€2.00
31.12.23
-15.88%
16.12.21

Could be very worthwhile Investment >20% year
IfYouCanDreamItYouCanDoIt 
15.11.21 60%
buy
Valneva SE

Start price
Target price
Perf. (%)
€21.24
15.11.21
€25.00
15.11.22
33.24%
27.11.21

Fair valuation
Very Future proof/growth oriented business model
Could be very worthwhile Investment >20% year
Higher risks for its business
skatcup 
15.11.21 90%
buy
OncoCyte Corp

Start price
Target price
Perf. (%)
€2.58
15.11.21
€4.00
15.11.22
-86.43%
16.11.22

krebskrebs 
15.11.21 50%
sell
Evofem Biosciences Inc.

Start price
Target price
Perf. (%)
€9.04
14.11.21
€4.50
31.12.23
-21.76%
16.11.21

Could be very worthwhile Investment >20% year
IfYouCanDreamItYouCanDoIt 
14.11.21 60%
buy
Kezar Life Sciences

Start price
Target price
Perf. (%)
€7.20
14.11.21
-
14.11.22
56.94%
16.11.21

blaugold 
14.11.21 50%
buy
Puma Biotechnology Inc.

Start price
Target price
Perf. (%)
€3.50
14.11.21
-
14.11.22
-18.26%
28.11.21

quelbe60 
14.11.21 50%
buy
Organigram Holdings Inc.

Start price
Target price
Perf. (%)
€8.04
14.11.21
-
14.11.22
-9.27%
26.11.21

michaelkr 
14.11.21 50%
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€13.55
14.11.21
-
14.11.22
-24.18%
26.11.21

michaelkr 
14.11.21 50%
buy
Cymabay Therapeutics Inc

Start price
Target price
Perf. (%)
€3.98
14.11.21
-
14.11.22
-22.05%
28.11.21

bundfuture 
14.11.21 50%
buy
Amarin Corp. ADR

Start price
Target price
Perf. (%)
€3.53
14.11.21
-
14.11.22
-7.37%
27.11.21

daimler1 
14.11.21 50%
buy
Puma Biotechnology Inc.

Start price
Target price
Perf. (%)
€3.50
14.11.21
-
14.11.22
-16.17%
26.11.21

melinda 
14.11.21 30%
sell
Curis Inc.

Start price
Target price
Perf. (%)
€5.06
14.11.21
-
14.11.22
-83.10%
15.11.22

Probably not worthwhile Investment
Lokrim 
14.11.21 20%
buy
ALK-Abelló A/S B

Start price
Target price
Perf. (%)
€22.33
13.11.21
€24.00
13.11.22
-37.17%
14.11.22

Future proof or reliable business model
Could be worthwhile Investment >10% per year
tbackenh 
13.11.21 80%
buy
Hexo Corp.

Start price
Target price
Perf. (%)
€22.26
13.11.21
€28.00
13.11.22
-88.09%
14.11.22

Higher risks for its business
tbackenh 
13.11.21 50%
buy
Novo Nordisk A/S

Start price
Target price
Perf. (%)
€99.36
13.11.21
-
13.11.22
10.69%
14.07.22

shnizdo 
13.11.21 0%
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€143.04
13.11.21
-
13.11.22
16.12%
08.05.22

NightTrain 
13.11.21 50%
sell
Catalyst Biosciences Inc

Start price
Target price
Perf. (%)
€0.79
13.11.21
€0.000
13.11.22
-26.11%
27.11.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
mixitrader 
13.11.21 50%
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€13.55
13.11.21
-
13.11.22
-69.88%
14.11.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
Maxi_Scalibusa 
13.11.21 0%